← FDA DRUG APPROVALS

FDA ANDA · ANDA091209

NORETHINDRONE

Sponsor: GLENMARK PHARMS LTD

APPLICATION
ANDA091209
TYPE
ANDA
ORIGINAL APPROVAL
2010-07-22
LATEST ACTION
2023-05-24
ROUTE
ORAL, ORAL-28
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

NORETHINDRONEPrescription
NORETHINDRONE 0.35MG · TABLET · ORAL-28

Approval history

2023-05-24Labeling · Supplement 10 · standardAP
2015-05-14Labeling · Supplement 5 · standardAP
2013-03-29Labeling · Supplement 3 · standardAP
2012-07-31Labeling · Supplement 2AP
2010-07-22OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →